This policy brief examines lessons learned from the Xpert MTB/RIF TB test buy-down and provides recommendations and pro-access conditions that should be applied to R&D funding, buy-down, and other market intervention agreements for COVID-19 diagnostics.
Treatment Action Group’s independent, peer-reviewed analysis found public investment in the development of bedaquiline was up to five times that of Johnson and Johnson. This finding appears in the new PLOS ONE article, “Public Investments in the Clinical Development of Bedaquiline.”
Treatment Action Group (TAG) strongly condemns alleged bullying, harassment, and racism directed toward staff and contractors of the Stop TB Partnership, as reported by The New York Times. As a long-term and current grantee of the Stop TB Partnership, we stand in solidarity with current and former staff and contractors whom this harassment and racism has affected.
As the COVID-19 pandemic continues to radically shift the global health landscape and alter government/donor commitments, TAG has released this timely brief to explore the impact of COVID-19 on TB research and development (R&D), and how tools, concepts, capacity, and…
In these two webinars, Treatment Action Group (TAG) launched the two latest additions to our series of materials designed for community leaders, An Activist’s Guide to Treatment for Drug-Resistant Tuberculosis and An Activist’s Guide to Tuberculosis Diagnostic Tools.
Our publication, An Activist’s Guide to Tuberculosis Diagnostic Tools, details the latest WHO recommendations, the array of available TB diagnostic tools, and how these tools should be optimally used in country programs, including to support TB screening and diagnosis among special populations such as children, people with extrapulmonary TB, and people living with HIV/AIDS (PLWHA).
Treatment Action Group welcomes the Global Drug Facility / Stop TB Partnership's negotiation of what amounts to a 32% savings on bedaquiline, the backbone of improved, all-oral regimens for treating drug-resistant TB.
The English version of this publication updated 2024. Please refer to the earlier versions on this page if you need languages other than English. English version updated April 2020. The updated guide reflects new information from recently completed clinical…
On Friday, April 3, Treatment Action Group (TAG) and Médecins Sans Frontières (MSF), and the Global Coalition of TB Activists (GCTA) held a webinar on the price of Xpert tests for COVID-19, TB, HIV, HCV and other diseases.
Last week, Treatment Action Group was pleased to receive the World Health Organization’s (WHO) update to its guidance on TB preventive therapy (TPT).